Research News

Maintenance Pazopanib in Ovarian Cancer: No Survival Benefit, High Rate of Complications

(Sept. 25, 2014) Maintenance therapy with the oral agent pazopanib improved progression free survival (PFS) by a median of 5.6 months in patients with advanced ovarian cancer but did not impact overall survival, according to the results of a phase III randomized trial reported in the Journal of Clinical... 

OCRF Research Finds Metastasis Promoted by Mesothelial Cells

Ernst Lengyel, MD, PhD A new study in the Journal of Clinical Investigation indicates that mesothelial cells actively promote the spread of ovarian cancer. Using a three dimensional culture model of ovarian cancer metastasis, OCRF grantee and Scientific Advisory Committee Member Ernst Lengyel, MD, PhD,... 

Ovarian Cancer Dream Team Call for Ideas Now Open

The American Association for Cancer Research is now accepting submissions of ideas for the new Stand Up To Cancer Ovarian Cancer Translational Research Dream Team Grant that will offer up to $6 million in research funding, which includes $3 million provided by the leading funder, OCRF. The Stand Up...